Graphical abstract from Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes, by Bailey, Flatt, and Conlon, licensed under CC BY 4.0 Subscribe by email to follow the accumulating evidence and observations that shape our view of health, obesity, and policy.
Huttenlocher and Dabholkar, 1997)
The fourth peptide in KLOW isn't wasted on you, but you don't need the inflammation modulation right out of the gate
Baseline plasma IGF-I concentrations were similar in both groups (mean +/- SEM, 106 +/- 9 micrograms/L), approximately half that observed in healthy young adults
Williams et al., Anesth Analg , 2009)
Moreno-Sanchez, R., Gallardo-Perez, J